Orbimed Advisors LLC Neurocrine Biosciences Inc Transaction History

Orbimed Advisors LLC

  • $3.69 Billion
  • Q4 2024

A detailed history of Orbimed Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 938,120 shares of NBIX stock, worth $107 Million. This represents 3.47% of its overall portfolio holdings.

Number of Shares
938,120
Previous 302,220 210.41%
Holding current value
$107 Million
Previous $34.8 Million 268.03%
% of portfolio
3.47%
Previous 0.82%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$111.62 - $139.44 $71 Million - $88.7 Million
635,900 Added 210.41%
938,120 $128 Million
Q3 2024

Nov 14, 2024
SELL
$114.58 - $153.15 $16.7 Million - $22.4 Million
-145,980 Reduced 32.57%
302,220 $34.8 Million
Q2 2024

Aug 14, 2024
BUY
$130.86 - $143.19 $3.28 Million - $3.59 Million
25,100 Added 5.93%
448,200 $61.7 Million
Q1 2024

May 15, 2024
SELL
$130.4 - $143.74 $12.5 Million - $13.8 Million
-96,179 Reduced 18.52%
423,100 $58.4 Million
Q4 2023

Feb 14, 2024
BUY
$106.07 - $132.76 $11 Million - $13.7 Million
103,379 Added 24.86%
519,279 $68.4 Million
Q3 2023

Nov 14, 2023
SELL
$94.02 - $117.1 $6.87 Million - $8.56 Million
-73,100 Reduced 14.95%
415,900 $46.8 Million
Q1 2023

May 15, 2023
SELL
$94.11 - $123.02 $18.7 Million - $24.4 Million
-198,700 Reduced 28.89%
489,000 $49.5 Million
Q4 2022

Feb 14, 2023
SELL
$106.72 - $127.06 $22.3 Million - $26.5 Million
-208,845 Reduced 23.29%
687,700 $82.1 Million
Q3 2022

Nov 14, 2022
BUY
$92.03 - $107.81 $4.33 Million - $5.07 Million
47,000 Added 5.53%
896,545 $95.2 Million
Q2 2022

Aug 15, 2022
SELL
$75.79 - $100.07 $1.97 Million - $2.6 Million
-25,970 Reduced 2.97%
849,545 $82.8 Million
Q1 2022

May 16, 2022
SELL
$72.45 - $94.81 $4.09 Million - $5.35 Million
-56,400 Reduced 6.05%
875,515 $82.1 Million
Q4 2021

Feb 14, 2022
SELL
$79.65 - $106.22 $20.7 Million - $27.6 Million
-260,100 Reduced 21.82%
931,915 $79.4 Million
Q3 2021

Nov 15, 2021
SELL
$86.18 - $99.03 $3.37 Million - $3.87 Million
-39,100 Reduced 3.18%
1,192,015 $114 Million
Q2 2021

Aug 16, 2021
SELL
$89.43 - $102.27 $6.31 Million - $7.22 Million
-70,600 Reduced 5.42%
1,231,115 $120 Million
Q3 2020

Nov 16, 2020
BUY
$96.16 - $135.15 $11.1 Million - $15.7 Million
115,800 Added 9.76%
1,301,715 $125 Million
Q2 2020

Aug 14, 2020
BUY
$85.09 - $130.36 $2.63 Million - $4.03 Million
30,900 Added 2.68%
1,185,915 $145 Million
Q1 2020

May 15, 2020
BUY
$75.11 - $113.76 $16.5 Million - $24.9 Million
219,045 Added 23.4%
1,155,015 $100 Million
Q4 2019

Feb 14, 2020
SELL
$86.8 - $118.57 $55.5 Million - $75.8 Million
-639,200 Reduced 40.58%
935,970 $101 Million
Q3 2019

Nov 14, 2019
SELL
$83.82 - $101.5 $21.6 Million - $26.2 Million
-258,030 Reduced 14.08%
1,575,170 $142 Million
Q1 2019

May 15, 2019
BUY
$69.31 - $91.53 $92.8 Million - $123 Million
1,339,000 Added 270.94%
1,833,200 $162 Million
Q4 2018

Feb 14, 2019
BUY
$68.32 - $124.36 $24.3 Million - $44.3 Million
356,400 Added 258.64%
494,200 $35.3 Million
Q2 2018

Aug 14, 2018
BUY
$75.3 - $105.99 $4.73 Million - $6.66 Million
62,800 Added 83.73%
137,800 $13.5 Million
Q1 2018

May 15, 2018
BUY
$75.88 - $92.43 $5.69 Million - $6.93 Million
75,000 New
75,000 $6.22 Million
Q4 2017

Feb 14, 2018
SELL
$58.53 - $77.59 $16.7 Million - $22.1 Million
-284,841 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$47.97 - $61.28 $13.7 Million - $17.5 Million
284,841
284,841 $17.5 Million

Others Institutions Holding NBIX

# of Institutions
655
Shares Held
96.6M
Call Options Held
282K
Put Options Held
281K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $10.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email